MedMira CEO Hermes Chan Named Top Bioscience Innovator of 2007 by The Economist



    HALIFAX, Oct. 19 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a global market leader in premium rapid diagnostic solutions,
announced today that company President and CEO, Hermes Chan was named the Top
Bioscience Innovator of 2007 at The Economist's Sixth Annual Innovation Awards
Ceremony and Summit last night in London, England. This prestigious
international event celebrates and explores the achievements of the men and
women whose radical ideas have had a significant impact on the world.
    "I am truly honoured to receive this award from The Economist," said
Hermes Chan, President and CEO of MedMira Inc. "This distinguished award
brings international recognition to MedMira and the world class product we
have developed here in Nova Scotia. The research and development environment
in Canada and Nova Scotia enables innovation, resulting in high quality,
internationally recognized inventions like ours."
    Mr. Chan, along with his former mentor and professor, Abdullah Kirumira,
was recognized with the innovation award for his invention of the rapid
flow-through diagnostic platform. Since inception in 1993 at a Nova Scotia
university science lab, Mr. Chan's invention has evolved to become the core
product upon which MedMira was built and the world's only rapid diagnostic
platform for the simultaneous detection of infectious diseases such as HIV and
Hepatitis C and B. Applications developed on Mr. Chan's patented rapid
diagnostic platform have earned approvals from international health care
regulators and agencies including Health Canada, the US Food and Drug
Administration, China's State Food and Drug Administration and the European CE
Mark.
    "On behalf of the entire MedMira team, our private and public sector
partners, and supporters, I would like to extend congratulations to Hermes on
receiving this important award, it is truly well deserved" said Stephen Sham,
Chairman, MedMira Inc. "This award from The Economist recognizes Hermes' many
years of hard work and MedMira's unyielding commitment to quality. Such global
recognition once again demonstrates that MedMira is on the path to greater
international success and profitability. "
    Following the awards, Mr. Chan participated in a half-day interactive
summit run by The Economist where the 2007 Innovation Award Winners shared
their achievements in innovation and how their ideas became successes. They
also discussed the role innovation played in their respective industries and
organisations, and how they see innovation shaping their future business
strategies.

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
European Union.
    In January 2006, MedMira launched the Maple Biosciences division to
develop and commercialize diagnostic instruments based on two revolutionary
biosensor-based technology platforms. The solutions developed by Maple
Biosciences will enable routine laboratory tests to be performed in a matter
of minutes, increasing laboratory automation, streamlining the diagnosis of
multiple conditions and diseases and positioning MedMira to be a leading
participant in the emerging fields of personalized medicine and molecular
diagnostics. For more information visit www.maplebio.com.
    MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada with a representative office in China. Maples
Biosciences' labs are located in Toronto, Ontario. For more information visit
MedMira's website at www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.




For further information:

For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, ir@medmira.com

Organization Profile

MedMira Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890